Abstract
Proteins and small peptides (growth factors and hormones) are key molecules in maintaining cellular homeostasis. To that end, Notch signaling pathway proteins are known to play critical roles in maintaining the balance between cell proliferation, differentiation and apoptosis, and thus it has been suggested that Notch may be responsible for the development and progression of human malignancies. Therefore, the Notch signaling pathway proteins may present novel therapeutic targets, which could have promising therapeutic impact on eradicating human malignancies. This review describes the role of Notch signaling pathway proteins in cancer and how its deregulation is involved in tumor development and progression leading to metastasis and the ultimate demise of patients diagnosed with cancer. Further, we summarize the role of several Notch inhibitors especially “natural agents” that could represent novel therapeutic strategies targeting Notch signaling toward better treatment outcome of patients diagnosed with cancer.
Keywords: Notch, cancer, signal pathway, review, natural agents, cancer therapy, γ-secretase inhibitors, oncogene
Current Protein & Peptide Science
Title: Notch Signaling Proteins: Legitimate Targets for Cancer Therapy
Volume: 11 Issue: 6
Author(s): Zhiwei Wang, Yiwei Li and Fazlul H. Sarkar
Affiliation:
Keywords: Notch, cancer, signal pathway, review, natural agents, cancer therapy, γ-secretase inhibitors, oncogene
Abstract: Proteins and small peptides (growth factors and hormones) are key molecules in maintaining cellular homeostasis. To that end, Notch signaling pathway proteins are known to play critical roles in maintaining the balance between cell proliferation, differentiation and apoptosis, and thus it has been suggested that Notch may be responsible for the development and progression of human malignancies. Therefore, the Notch signaling pathway proteins may present novel therapeutic targets, which could have promising therapeutic impact on eradicating human malignancies. This review describes the role of Notch signaling pathway proteins in cancer and how its deregulation is involved in tumor development and progression leading to metastasis and the ultimate demise of patients diagnosed with cancer. Further, we summarize the role of several Notch inhibitors especially “natural agents” that could represent novel therapeutic strategies targeting Notch signaling toward better treatment outcome of patients diagnosed with cancer.
Export Options
About this article
Cite this article as:
Wang Zhiwei, Li Yiwei and H. Sarkar Fazlul, Notch Signaling Proteins: Legitimate Targets for Cancer Therapy, Current Protein & Peptide Science 2010; 11 (6) . https://dx.doi.org/10.2174/138920310791824039
DOI https://dx.doi.org/10.2174/138920310791824039 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Processes Exploited as Drug Targets for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Human Papillomavirus DNA and E6/E7 mRNA Testing as Triage in Liquid-Based Cytology Samples from Primary Screening
Current Pharmaceutical Design Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
Recent Patents on Anti-Cancer Drug Discovery Recent Development, Applications, and Perspectives of Mesoporous Silica Particles in Medicine and Biotechnology
Current Medicinal Chemistry MARK1 is a Novel Target for miR-125a-5p: Implications for Cell Migration in Cervical Tumor Cells
MicroRNA Novel Approaches to Cancer Therapy Using Oncolytic Viruses
Current Molecular Medicine Disulfiram, and Disulfiram Derivatives as Novel Potential Anticancer Drugs Targeting the Ubiquitin Proteasome System in Both Preclinical and Clinical Studies
Current Cancer Drug Targets Metabolomic Biomarkers in Gynecology: A Treasure Path or a False Path?
Current Medicinal Chemistry Plumbagin Inhibits Breast Tumor Bone Metastasis and Osteolysis by Modulating the Tumor-Bone Microenvironment
Current Molecular Medicine Therapeutic Exploitation of Endogenous Anti-Inflammatory Mechanisms:Old and New Leads
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT
Current Pharmaceutical Design Polyploidy: The Link Between Senescence and Cancer
Current Pharmaceutical Design COX-2 Selective Inhibitors, Carbonic Anhydrase Inhibition and Anticancer Properties of Sulfonamides Belonging to This Class of Pharmacological Agents
Mini-Reviews in Medicinal Chemistry Proteomics Approach to Illustrate Drug Action Mechanisms
Current Drug Discovery Technologies Peptides to Target Tumor Vasculature and Lymphatics for Improved Anti-Angiogenesis Therapy
Current Cancer Drug Targets Imaging Studies in Hypercalcemia
Current Medicinal Chemistry Biocompatibility and Solubility of Fe3O4-BSA Conjugates with Human Blood
Current Nanoscience Tumor Angiogenesis: A Potential Target In Cancer Control by Phytochemicals
Current Cancer Drug Targets PET and SPECT Radiotracers to Assess Function and Expression of ABC Transporters In Vivo
Current Drug Metabolism Advanced Assessment of the Endogenous Hormone Level as a Potential Biomarker of the Urogenital Tract Cancer
Combinatorial Chemistry & High Throughput Screening